Integrated Nicotine Replacement and Behavioral Support to Reduce Smoking in Opioid Agonist Therapy
Sign Up to like & getrecommendations! Published in 2025 at "JAMA Psychiatry"
DOI: 10.1001/jamapsychiatry.2024.4801
Abstract: Key Points Question Can an integrated intervention combining nicotine replacement and brief behavioral support reduce the number of cigarettes smoked among patients receiving opioid agonist therapy? Findings In this randomized clinical trial including 259 participants,… read more here.
Keywords: opioid agonist; nicotine replacement; agonist therapy; behavioral support ... See more keywords
Preoperative treatment with dopamine agonist therapy influences surgical outcome in prolactinoma: a retrospective single-center on 159 patients
Sign Up to like & getrecommendations! Published in 2024 at "Acta Neurochirurgica"
DOI: 10.1007/s00701-024-06198-5
Abstract: Prolactinoma account to the most common pituitary adenomas and current therapy regime constitutes of dopamine agonist therapy (DA) and surgery in selected cases [17]. Due to tumor fibrosis induced by previous DA therapy, surgical removal… read more here.
Keywords: surgical outcome; treatment; therapy; dopamine agonist ... See more keywords
Treatment of Chronic Hepatitis C in Patients Receiving Opioid Agonist Therapy: A Review of Best Practice.
Sign Up to like & getrecommendations! Published in 2018 at "Infectious disease clinics of North America"
DOI: 10.1016/j.idc.2018.02.001
Abstract: Injection drug use is the most common transmission route for hepatitis C. High rates of infection are observed among individuals on opioid agonist therapy. Although people who inject drugs carry the highest burden, few have… read more here.
Keywords: hepatitis; treatment; opioid agonist; agonist therapy ... See more keywords
Macroprolactinoma-Induced Syndrome of Inappropriate Antidiuresis and Its Reversal with Dopamine Agonist Therapy.
Sign Up to like & getrecommendations! Published in 2022 at "Laboratory medicine"
DOI: 10.1093/labmed/lmac025
Abstract: Hyponatremia is an uncommon manifestation of pituitary adenomas. Herein, I report a case of syndrome of inappropriate antidiuresis (SIAD) caused by a macroprolactinoma that rapidly resolved with dopamine agonist therapy. A 29-year-old White woman presented… read more here.
Keywords: syndrome inappropriate; agonist therapy; dopamine agonist; macroprolactinoma ... See more keywords
TLR Agonist Therapy of Metastatic Breast Cancer in Mice
Sign Up to like & getrecommendations! Published in 2023 at "Journal of Immunotherapy (Hagerstown, Md. : 1997)"
DOI: 10.1097/cji.0000000000000467
Abstract: Toll-like receptor (TLR) 7/8 and 9 agonists stimulate an innate immune response that supports the development of tumor-specific immunity. Previous studies showed that either agonist individually could cure mice of small tumors and that when… read more here.
Keywords: tlr agonist; breast; mice; agonist therapy ... See more keywords
Reduction in mortality risk with opioid agonist therapy: a systematic review and meta‐analysis
Sign Up to like & getrecommendations! Published in 2019 at "Acta Psychiatrica Scandinavica"
DOI: 10.1111/acps.13088
Abstract: Opioid agonist therapies are effective medications that can greatly improve the quality of life of individuals with opioid use disorder. However, there is significant uncertainty about the risks of cause‐specific mortality in and out of… read more here.
Keywords: reduction mortality; risk opioid; mortality risk; agonist therapy ... See more keywords
GLP-1 Receptor Agonist Therapy and Cardiorenal Outcomes in Patients ≥ 80 Years Old With Type 2 Diabetes.
Sign Up to like & getrecommendations! Published in 2025 at "Journal of the American Geriatrics Society"
DOI: 10.1111/jgs.70187
Abstract: Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) have demonstrated potential in improving glycemic control and reducing adverse outcomes in patients with Type 2 diabetes mellitus (T2DM); however, their efficacy in individuals aged 80 years and older remains… read more here.
Keywords: type diabetes; receptor agonist; glp receptor; outcomes patients ... See more keywords
Long-acting injectable buprenorphine – ‘best practice’ opioid agonist therapy for Australian prisoners
Sign Up to like & getrecommendations! Published in 2022 at "Australasian Psychiatry"
DOI: 10.1177/10398562211059086
Abstract: Objective To consider opioid agonist therapy in prisons. Conclusions Given the substantial risks of substance misuse by prisoners, long-acting injectable buprenorphine should be adopted as ‘best practice’ treatment in Australian prison populations. read more here.
Keywords: long acting; acting injectable; best practice; agonist therapy ... See more keywords
Status epilepticus induced by treatment with dopamine agonist therapy for giant prolactinoma: a case report
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Medical Case Reports"
DOI: 10.1186/s13256-018-1939-x
Abstract: BackgroundDopamine agonists are the standard first-line medical therapy for prolactinoma. We report a rare case of giant prolactinoma with a first epileptic seizure due to rapid reduction of the tumor as a complication of dopamine… read more here.
Keywords: agonist therapy; case; prolactinoma; therapy ... See more keywords
SUN-688 Unexpected Consequences: Guillain-Barre Syndrome Following GLP-1 Agonist Therapy
Sign Up to like & getrecommendations! Published in 2025 at "Journal of the Endocrine Society"
DOI: 10.1210/jendso/bvaf149.195
Abstract: Abstract Disclosure: S. Obialo: None. R. Jaber: None. N. Sukthanker: None. Introduction: Glucagon-like peptide-1 receptor (GLP-1) agonists are commonly prescribed for type 2 diabetes mellitus (T2DM) and obesity. Typical side effects include gastrointestinal symptoms such… read more here.
Keywords: glp agonist; therapy; sun 688; case ... See more keywords
Retrospective Analysis of Hospitalized Patients with Type 2 Diabetes Mellitus Treated with Glucagon-Like Peptide 1 Receptor Agonist Therapy
Sign Up to like & getrecommendations! Published in 2023 at "Southern Medical Journal"
DOI: 10.14423/smj.0000000000001511
Abstract: The authors studied the impact and safety of glucagon-like peptide 1 (GLP-1) receptor agonist therapy in hospitalized diabetes mellitus patients with chronic kidney disease. They found that the use of GLP-1 receptor agonist therapy had… read more here.
Keywords: receptor agonist; glp receptor; gfr stages; agonist therapy ... See more keywords